Trends in the Prescribing of Psychotropic Medications to Preschoolers
Overview
Affiliations
Context: Recent reports on the use of psychotropic medications for preschool-aged children with behavioral and emotional disorders warrant further examination of trends in the type and extent of drug therapy and sociodemographic correlates.
Objectives: To determine the prevalence of psychotropic medication use in preschool-aged youths and to show utilization trends across a 5-year span.
Design: Ambulatory care prescription records from 2 state Medicaid programs and a salaried group-model health maintenance organization (HMO) were used to perform a population-based analysis of three 1-year cross-sectional data sets (for the years 1991, 1993, and 1995).
Setting And Participants: From 1991 to 1995, the number of enrollees aged 2 through 4 years in a Midwestern state Medicaid (MWM) program ranged from 146,369 to 158,060; in a mid-Atlantic state Medicaid (MAM) program, from 34,842 to 54,237; and in an HMO setting in the Northwest, from 19,107 to 19,322.
Main Outcome Measures: Total, age-specific, and gender-specific utilization prevalences per 1000 enrollees for 3 major psychotropic drug classes (stimulants, antidepressants, and neuroleptics) and 2 leading psychotherapeutic medications (methylphenidate and clonidine); rates of increased use of these drugs from 1991 to 1995, compared across the 3 sites.
Results: The 1995 rank order of total prevalence in preschoolers (per 1000) in the MWM program was: stimulants (12.3), 90% of which represents methylphenidate (11.1); antidepressants (3.2); clonidine (2.3); and neuroleptics (0.9). A similar rank order was observed for the MAM program, while the HMO had nearly 3 times more clonidine than antidepressant use (1.9 vs 0.7). Sizable increases in prevalence were noted between 1991 and 1995 across the 3 sites for clonidine, stimulants, and antidepressants, while neuroleptic use increased only slightly. Methylphenidate prevalence in 2- through 4-year-olds increased at each site: MWM, 3-fold; MAM, 1.7-fold; and HMO, 3.1-fold. Decreases occurred in the relative proportions of previously dominant psychotherapeutic agents in the stimulant and antidepressant classes, while increases occurred for newer, less established agents.
Conclusions: In all 3 data sources, psychotropic medications prescribed for preschoolers increased dramatically between 1991 and 1995. The predominance of medications with off-label (unlabeled) indications calls for prospective community-based, multidimensional outcome studies.
Antipsychotic off-label use in the 21st century: An enduring public health concern.
Verdoux H Dialogues Clin Neurosci. 2025; 27(1):1-12.
PMID: 39791867 PMC: 11789223. DOI: 10.1080/19585969.2025.2449833.
West L, Mooney S, Chavez L, Beck A, Clarke G, Pabiniak C J Child Adolesc Psychopharmacol. 2024; 34(7):310-318.
PMID: 38743639 PMC: 11807901. DOI: 10.1089/cap.2024.0007.
Al-Harthi H, Al-Huseini S, Al-Shukaili M, Chan M, Al-Mahrouqi T, Al-Breiki M Sultan Qaboos Univ Med J. 2023; 23(2):190-197.
PMID: 37377817 PMC: 10292593. DOI: 10.18295/squmj.8.2022.049.
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebo O, Storm M, Ribeiro J, Skoog M, Groth C, Callesen H Cochrane Database Syst Rev. 2023; 3:CD009885.
PMID: 36971690 PMC: 10042435. DOI: 10.1002/14651858.CD009885.pub3.
Systematic Review of Gender-Specific Child and Adolescent Mental Health Care.
Herrmann L, Reiss F, Becker-Hebly I, Baldus C, Gilbert M, Stadler G Child Psychiatry Hum Dev. 2023; 55(6):1487-1501.
PMID: 36849848 PMC: 11485121. DOI: 10.1007/s10578-023-01506-z.